Johnny Stilou Email Address

Chief Financial Officer

Veloxis Pharmaceuticals (LCP) is an emerging specialty pharmaceutical company, focused on certain cardiovascular indications and organ transplantation in particular. The intention is to approach the transplantation market through our own, hospital-based specialist sales force and to use marketing and sales partners for the cardiovascular indications. We believe that our proprietary MeltDose(r) technology platform enables us to develop drugs which achieve the same efficacy as currently commercialized drugs, but at lower doses. The results are generally better bioavailability, a reduction in potential interaction with food and other drugs, and in some cases, reduced side effects.

I am an associate in Freshfields' financial services regulatory team with a particular interest in investment management and funds.|I work with a range of clients including banks, asset managers, investment managers and funds advising on financial services regulatory, compliance and general corporate governance issues. I have advised on the structuring, formation, regulation and marketing of both onshore and offshore funds (whether to retail or professional investors) and have developed a particular interest in UCITS and AIFMD-related advice. My recent work includes advising a number of clients on their preparations for the implementation of the AIFMD.|I also advise on the regulatory issues involved in establishing and operating financial services businesses in the UK and advising on the regulatory aspects of M&A transactions in the financial services sector.